PubMed HealthSearch

PubMed · 2866053

Hyperthyroid heart disease.

Abstract

The importance of cardiovascular system involvement in hyperthyroidism has been recognized for many years. In the middle-aged and elderly patient, often with mild but prolonged elevation of plasma thyroid hormones, symptoms and signs of heart failure and complicating atrial fibrillation may dominate the clinical picture and mask the more classical endocrine manifestations of the disease. Pitfalls in diagnosis and the importance of early recognition and treatment are discussed. Despite experimental evidence for a short-term inotropic action of thyroid hormone excess, clinical data support the existence of a reversible cardiomyopathy in hyperthyroidism with impaired contractile reserve. Enhanced myocardial performance at rest primarily reflects the peripheral actions of thyroid hormone excess. Most, if not all, of the cardiac abnormalities return to normal once a euthyroid state has been achieved, although atrial fibrillation may persist in a minority. Optimum treatment requires rapid and definitive antithyroid therapy, usually using a large dose of radio-iodine, and rapid control of heart failure. Systemic anticoagulation is indicated in the presence of atrial fibrillation and should be continued until sinus rhythm has been present for at least three months, either spontaneously or after cardioversion.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J C Forfar, G C Caldwell. 1985. Hyperthyroid heart disease.. https://doi.org/10.1016/s0300-595x(85)80044-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Beta-adrenergic blockers as cardioprotective agents.

The evidence supporting and describing cardioprotective effects of beta-adrenergic blocker treatment is surveyed. Details of the many studies that individually and collectively document the ability of long-term and acute beta-blocker therapy to reduce overall mortality, sudden cardiovascular death, and nonfatal reinfarction in patients surviving or experiencing a myocardial infarction are described. A discussion of the mechanisms by which beta blockers probably and theoretically achieve these benefits includes the suggestion that they may reduce plaque rupture, thus indirectly inhibiting thrombosis. It is also suggested that, in the future, further cardioprotective benefits may accrue to the use of beta blockers in conjunction with thrombolysis and of beta blockers with a duration of action sustained throughout a full 24 hours.

Adrenergic beta-Antagonists

[Developments in the treatment of myocardial infarction in Switzerland 1986-1990: results of a population survey].

The Swiss cantons of Vaud and Fribourg participate in the international MONICA project (MONI-toring of trends and determinants in CArdiovascular disease). Within this context, drug therapies and procedures were recorded during two separate years (1986 and 1990) for all hospitalizations of men aged 25 to 64 with the diagnosis of myocardial infarction. The medical files were reviewed to classify this diagnosis as possible or definite on the basis of the symptoms, the ECG results and the enzymatic tests. The two study populations (n = 318 in 1986 and n = 332 in 1990) are comparable with respect to age, history of ischemic heart disease and initial care. In 1990, half of the patients arrived at hospital in less than 3 hours, the median time delay being 4 hours for those first attending a general practitioner and 2 hours for those transferred directly. The frequency of treatments between 1986 and 1990 is compared only for cases with a definite diagnosis of myocardial infarction (respectively n = 217 and n = 223). The proportion of patients given thrombolytic therapy rose from 9% to 44% (p < 0.005) and from 51% to 95% (p < 0.005) for those treated with antiplatelet drugs, whereas the proportion fell from 72% to 55% (p < 0.005) for calcium blockers and from 33% to 24% (p < 0.05) for inotropic drugs. The use of anticoagulants (in 98% of patients) and of beta blockers (in 57%) remained stable across time.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Antagonists